2023 Articles
Extracorporeal membrane oxygenation for COVID-19-related acute respiratory distress syndrome: a narrative review
A growing body of evidence supports the use of extracorporeal membrane oxygenation (ECMO) for severe acute respiratory distress syndrome (ARDS) refractory to maximal medical therapy. ARDS may develop in a proportion of patients hospitalized for coronavirus disease 2019 (COVID-19) and ECMO may be used to manage patients refractory to maximal medical therapy to mitigate the risk of ventilator-induced lung injury and provide lung rest while awaiting recovery. The mortality of COVID-19-related ARDS was variously reassessed during the pandemic. Veno-venous (VV) ECMO was the default choice to manage refractory respiratory failure; however, with concomitant severe right ventricular dysfunction, venoarterial (VA) ECMO or mechanical right ventricular assist devices with extracorporeal gas exchange (Oxy-RVAD) were also considered. ECMO has also been used to manage special populations such as pregnant women, pediatric patients affected by severe forms of COVID-19, and, in cases with persistent and seemingly irreversible respiratory failure, as a bridge to successful lung transplantation. In this narrative review, we outline and summarize the most recent evidence that has emerged on ECMO use in different patient populations with COVID-19-related ARDS.
Subjects
Files
- 40560_2023_Article_654.pdf application/pdf 200 KB Download File
Also Published In
- Title
- Journal of Intensive Care
- DOI
- https://doi.org/10.1186/s40560-023-00654-7
More About This Work
- Published Here
- July 22, 2024
Related Items
Notes
Extracorporeal membrane oxygenation, ECMO, COVID-19, ARDS, Respiratory failure, Extracorporeal life support